MaxCyte, Inc. Accounts Receivable, Credit Loss Expense (Reversal)
MaxCyte, Inc. (MXCT) reported Accounts Receivable, Credit Loss Expense (Reversal) of $35.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForDoubtfulAccounts · last filed 2026-08-13
- MaxCyte, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2025-12-31 was $6.00K.
- MaxCyte, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2025-09-30 was $19.00K.
- MaxCyte, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2024-12-31 was $0.00.
- MaxCyte, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2024-09-30 was $0.00.
- MaxCyte, Inc. accounts receivable, credit loss expense (reversal) for fiscal 2025 was $35.00K.
- MaxCyte, Inc. accounts receivable, credit loss expense (reversal) for fiscal 2024 was -$130.00K, a 176.02% decline from fiscal 2023.
- MaxCyte, Inc. accounts receivable, credit loss expense (reversal) for fiscal 2023 was $171.00K.
- MaxCyte, Inc. accounts receivable, credit loss expense (reversal) for fiscal 2020 was -$117.20K, a 316.24% decline from fiscal 2019.
| Period end | Accounts Receivable, Credit Loss Expense (Reversal) 3 month | Accounts Receivable, Credit Loss Expense (Reversal) 6 month | Accounts Receivable, Credit Loss Expense (Reversal) 6 month as first filed | Accounts Receivable, Credit Loss Expense (Reversal) 9 month | Accounts Receivable, Credit Loss Expense (Reversal) 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $25.00K derived: sum of 2 quarters · filed 2026-03-25 | $35.00K 10-K · filed 2026-03-25 | ||
| 2025-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $29.00K 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $10.00K 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | -$260.00K derived: sum of 3 quarters · filed 2026-03-25 | -$130.00K 10-K · filed 2026-03-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$260.00K derived: sum of 2 quarters · filed 2025-11-13 | -$130.00K 10-Q · filed 2025-11-13 | -$180.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$260.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$130.00K 10-Q · filed 2025-08-06 | -$180.00K derived: sum of 3 quarters · filed 2025-08-06 | -$189.00K derived: sum of 4 quarters · filed 2025-08-06 | |
| 2024-03-31 | $130.00K 10-Q · filed 2025-05-08 | $80.00K derived: sum of 2 quarters · filed 2025-05-08 | $71.00K derived: sum of 3 quarters · filed 2025-05-08 | ||
| 2023-12-31 | -$50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$59.00K derived: sum of 2 quarters · filed 2025-03-11 | $171.00K 10-K · filed 2025-03-11 | ||
| 2023-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $221.00K 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $230.00K 10-Q · filed 2024-08-06 | $230.20K 10-Q · filed 2023-08-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $0.00 derived: sum of 2 quarters · filed 2022-03-22 | -$117.20K 10-K · filed 2022-03-22 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$117.20K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$117.20K 10-Q · filed 2021-09-13 | ||||
| 2019-12-31 | $54.20K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |